Physiomics Share Discussion Threads

[davevt] 19/8/2020 20:54

Spud, Stig did.

And of course 5 years isn't nonsense, it's taken nearly ten to get through pre clinical.




'They don't hang around when it's life saving drugs'.

You really are a clueless ramper aren't you.

Do one.

[spudyoulike] 19/8/2020 20:45

Might I add lll data is in.

[bountyhunter] 19/8/2020 20:31

Should be double quotes, just saying.

[davevt] 19/8/2020 20:28

My word, only 10 years on and we are not even at clinical stage, which can be another 5 years, and fail, or the opposite, and that doesn't mean anything unless it can then get fda approval.

Quoting it like it's a reason to invest in pyc is blatant stupidity..you are talking absolute years, and based on another ramped floated company.

Who knows if the drug is junk or not, it doesn't matter. You think people are investing on an unknown percentage of a 'what if' that could be years away? 😂

..and proves my point all along. This is why pyc rarely gets any customers or contracts, because it only specialises in dosage prediction for cancer drugs only, in trials, and you can see the timeframe it takes for pharmas to develop drugs that would even need dosage prediction, and that's if they even choose to use pyc.

[spudyoulike] 19/8/2020 19:53

You're starting to sound like Albert.

[spudyoulike] 19/8/2020 19:41

I suggest you go over to the VAL board and tell them that it's not happening and see what response you get. You must think that the contract is void because it was signed in 2011? Again PYC/VAL are and were quite aware of the Timescale of getting the drug through clinical trials at the time the contract was signed. I can't believe I have to spell this out to you mate, honestly.

[spudyoulike] 19/8/2020 19:30

Dave, note: the next stage of VAL201’s preclinical programme. Pre-clinical! This was work done before clinical trials started! They have now finished l and ll and waiting on results for lll, coming quarter 3. It did happen Dave and IS happening. What don't you get?

[davevt] 19/8/2020 19:06

Spud, that's from 2011!

It NEVER HAPPENED.

[albert3591] 19/8/2020 17:36

And will not be.

[thehitman1] 19/8/2020 17:03

still not 17p.

[albert3591] 19/8/2020 16:56

Think of yesterday’s buyers,will they share your sentiment.

[tonytony4] 19/8/2020 16:48

Looks like derampers will be making the most of today's drop! Hold and add if you can.

[albert3591] 19/8/2020 16:26

Shoddy go on tell them what a bargain it is.stiggy post your rubbish old news again I forgot what it was.LOLOL

[albert3591] 19/8/2020 16:23

Nice intrastate drop,did you enjoy that newbies who bought at the top yesterday.Admit it you all fell for it.

[albert3591] 19/8/2020 16:16

So good is this share is it.I just can’t believe there are any shares for people to buy,strange that.

[spudyoulike] 19/8/2020 13:56

Dave, what the hell are you going on about? You are now showing how truly clueless or desperate or both you are. Have you read the RNS? Keep trying mate but this is just cringe worthy de-ramping. assist ValiRx to accelerate the development of its lead therapeutic, VAL201, and speed its progress through the next stage of VAL201’s preclinical programme to support the regulatory requirements prior to its entering clinical trials. The Agreement is on a revenue sharing basis, so that Physiomics will not receive a fee for their work but will receive a percentage of any licensing income received by ValiRx for the compound for use in treating prostate cancer, in due course.

[hodhasharon] 19/8/2020 13:24

dave's not bright enough to deramp. Just a thick newbie.

[tonytony4] 19/8/2020 13:20

Oh dear desperate derampers trying it on again! Clearly need to close out any short positions..

[davevt] 19/8/2020 13:16

Pyc does not get a royalty from VAL, or anyone else, because pyc is not involved in designing of the drug, or has rights to the drug, or anything in that route.

The sar 'licence fee' was just a Fee to use their algorithms in a trial basis only.

You're making out they would get a percentage of sales 🤣

All pyc does for customers is advise an optimum dose and frequency of the drug to be given to people in TRIALS ONLY, they don't even work out what it would be for the end consumer.




I love how this 'share is so good' that the incessant rampers will just lie openly.

[hodhasharon] 19/8/2020 08:27

VAL looks primed for news too. All good.

[the stigologist] 19/8/2020 08:26

VAL confirm newsflow due in Q3 and Q4 on VAL201

Physiomics entitled to share of any licensing income on VAL201

This could indeed be massive for PYC

If VAL201 is a moderate 'success' selling $100m a year even a 1% annual royalty would be worth $1m straight to the bottom line for PYC. Market would massively re-rate Physiomics if it had that sort of transformational news.

Physiomics have previously received a minor licence fee when SAR Sareum licenced a product to Sierra Oncology although that waa a v.early stage pre clinical licence

Licencing of a successful Phase 1/2 Prostate Cancer drug would be much bigger upfront numbers

Also been speculation recently whether we might be entitled to similar revenue share deals on Cyclacel (CYCC) succeses now that they seem on the front foot with cancer drugs and potential efficacy of those drugs in covid19.

The transformation of PYC into a royalty/licence fee play would be HUGE. The market loves royalty plays in mining/tech e.g. ARM because you get high quality, high margin, high visibility and long duration earnings with little risk/capital outlay